Spread of T lymphocyte immune responses to myelin epitopes with duration of multiple sclerosis

Journal of Neuropathology and Experimental Neurology

Volumn 64, Issue 5, 2005, Pages 371-377

  Davies, Selina ^a   Nicholson, Tim ^b   Laura, Matilde ^c   Giovannoni, Gavin ^b   Altmann, Daniel M ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Epitopes; Multiple sclerosis; Myelin; T lymphocytes

Indexed keywords

EPITOPE; MYELIN BASIC PROTEIN;

ADULT; AGED; ALLERGIC ENCEPHALITIS; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; CELL SPECIFICITY; CELL SPREADING; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNE RESPONSE; MALE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; T LYMPHOCYTE;

EID: 18244409880     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnen/64.5.371     Document Type: Article

References (37)

1. Hafler DA. Multiple sclerosis. J Clin Invest 2004;113:788-94
2. Zamvil S, Steinman L. Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis. Neuron 2003;38:685-88
3. Barnett M, Prineas J. Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion. Ann Neurol 2004;55:458-68
4. Haines J, Bradford Y, Garcia M, et al. Multiple susceptibility loci for multiple sclerosis. Hum Mol Genet 2002;11:2251-56
5. Steinman L. Immunotherapy of multiple sclerosis: The end of the beginning. Curr Opin Immunol 2001;13:597-600
6. Vanderlugt C, Miller S. Epitope spreading in immune-mediated diseases: Implications for immunotherapy. Nat Rev Immunol 2002;2:85-95
7. McCarron RM, Fallis RJ, McFarlin DE. Alterations in T cell antigen specificity and class II restriction during the course of chronic relapsing experimental allergic encephalomyelitis. J Neuroimmunol 1990;29:73-79
8. Lehmann P, Forsthuber T, Miller A, Sercarz E. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992;358: 155-57
9. McRae B, Vanderlugt C, Dal Canto M, Miller S. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J Exp Med 1995;182:75-85
10. Yu M, Johnson J, Tuohy V. A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: A basis for peptide-specific therapy after onset of clinical disease. J Exp Med 1996;183:1777-88
11. Vanderlugt C, Neville K, Nikevich K, Eager T, Bluestone J, Miller S. Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis. J Immunol 2000;164:670-78
12. Takacs K, Chandler P, Altmann D. Relapsing and remitting experimental allergic encephalomyelitis: A focused response to the encephalitogenic peptide rather than epitope spread. Eur J Immunol 1997;27:2927-34
13. Jones R, Bourdette D, Moes N, Vandenbark A, Offner H. Epitope spreading is not required for relapses in experimental autoimmune encephalomyelitis. J Immunol 2003;170:1690
14. Takacs K, Altmann D. The case against epitope spread in experimental allergic encephalomyelitis. Immunol Rev 1998;164:101-10
15. Tuohy V Yu M, Yin L, Kawczak J, Kinkel R. Spontaneous regression of primary autoreactivity during chronic progression of experimental autoimmune encephalomyelitis and multiple sclerosis. J Exp Med 1999;189:1033
16. Goebels N, Hofstetter H, Schmidt S, Brunner C, Wekerle H, Hohlfeld R. Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects. Epitope spreading versus clonal persistence. Brain 2000;123:508-13
17. Muraro P, Wandinger K, Bielekova B, et al. Molecular tracking of antigen-specific T cell clones in neurologic immune-mediated disorders. Brain 2003;126:20-31
18. Genain C, Zamvil S. Specific immunotherapy: One size does not fit all. Nat Med 2000;6:1098-100
19. Bielekova B, Sung M, Kadom N, Simon R, McFarland H, Martin R. Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis. J Immunol 2004;172:3893-904
20. Markovic-Plese S, Fukaura H, Zhang J, et al. T cell recognition of immunodominant and cryptic proteolipid protein epitopes in humans. J Immunol 1995;155:982-92
21. Trotter J, Pelfrey C, Trotter A, et al. T cell recognition of myelin proteolipid protein and myelin proteolipid protein peptides in the peripheral blood of multiple sclerosis and control subjects. J Neuroimmunol 1998;84:172-78
22. Ohashi T, Yamamura T, Inobe J, Kondo T, Kunishita T, Tabira T. Analysis of proteolipid protein (PLP)-specific T cells in multiple sclerosis: Identification of PLP 95-116 as an HLA-DR2,w15-associated determinant. Int Immunol 1995;7:1771-78
23. Kerlero de Rosbo N, Milo R, Lees MB, Burger D, Bernard CC, Ben-Nun AA. Reactivity to myelin antigens in multiple sclerosis: Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein J Clin Invest 1993;92:260-66
24. Wallstrom E, Khademi M, Andersson M, Weissert R, Linnington C, Olsson T. Increased reactivity to myelin oligodendrocyte glycoprotein peptides and epitope mapping in HLA DR2 (15)+ multiple sclerosis. Eur J Immunol 1998;28:3329
25. Valli A, Sette A, Kappos L, et al. Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. J Clin Invest 1993;91:616-28
26. Martin R, Jaraquemada D, Flerlage M, et al. Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J Immunol 1990;145:540-48
27. Ota K, Matsui M, Milford E, Mackin G, Weiner H, Hafler D. T cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 1990;346:183-85
28. Wucherpfennig K, Zhang J, Witek C, et al. Clonal expansion and persistence of human T cells specific for an immunodominant myelin basic protein peptide. J Immunol 1994;152:5581-92
29. Pette M, Fujita K, Wilkinson D, et al. Myelin autoreactivity in multiple sclerosis: Recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors. Proc Natl Acad Sci USA 1990;87:7968-72
30. Meinl E, Weber F, Drexler K, et al. Myelin basic protein-specific T lymphocyte repertoire in multiple sclerosis. Complexity of the response and dominance of nested epitopes due to recruitment of multiple T cell clones. J Clin Invest 1993;92:2633-43
31. Vergelli M, Kalbus M, Rojo S, et al. T cell response to myelin basic protein in the context of the multiple sclerosis-associated HLA-DR15 haplotype: Peptide binding, immunodominance and effector functions of T cells. J Neuroimmunol 1997;77:195-203
32. Mazza G, Ponsford M, Campbell M, Zajicek J, Wraith D. Diversity and dynamics of the T-cell response to MBP in DR2+ve individuals. Clin Exp Immunol 2002;128:538
33. Pender M, Csurhes P, Greer J, et al. Surges of increased T cell reactivity to an encephalitogenic region of myelin proteolipid protein occur more often in patients with multiple sclerosis than in healthy subjects. J Immunol 2000;165:5322-31
34. Sindern E, Patzold T, Ossege L, Gisevius A, Malin J. Expression of chemokine receptor CXCR3 on cerebrospinal fluid T-cells is related to active MRI lesion appearance in patients with relapsing-remitting multiple sclerosis. J Neuroimmunol 2002;131:186-90
35. Hellings N, Gelin G, Medaer R, et al. Longitudinal study of antimyelin T-cell reactivity in relapsing-remitting multiple sclerosis: Association with clinical and MRI activity. J Neuroimmunol 2002;126:143-60
36. Ristori G, Giubilei F, Giunti D, et al. Myelin basic protein intramolecular spreading without disease progression in a patient with multiple sclerosis. J Neuroimmunol 2000;110:240-43
37. Ellmerich S, Takacs K, Mycko M, et al. Disease-related epitope spread in a humanized T cell receptor transgenic model of multiple sclerosis. Eur J Immunol 2004;34:1839-48